AbbVie is paying $650 million for a dual-targeting immunotherapy from China’s RemeGen. Elsewhere, Alnylam missed an earnings ...
Vertex saw disappointments in 2022, that may be about to change. Profitability may improve as onerous hedging rolled off for Q4. Shares could double from here to around $18 on my estimates (range: $10 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback